Get the Stockscreener App
37.49
1.41%
0.52
Smith Nephew Plc Adr stock is traded at $37.49, with a volume of 603.87K.
It is up +1.41% in the last 24 hours and up +21.21% over the past month.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
See More
Previous Close:
$36.97
Open:
$37.21
24h Volume:
603.87K
Relative Volume:
0.64
Market Cap:
$15.83B
Revenue:
$5.81B
Net Income/Loss:
$412.00M
P/E Ratio:
39.88
EPS:
0.94
Net Cash Flow:
-
1W Performance:
+3.56%
1M Performance:
+21.21%
6M Performance:
+43.47%
1Y Performance:
+22.40%
1-Day Range:
$37.08
$37.58
1-Week Range:
$36.24
$37.58
52-Week Range:
$23.69
$37.58
Smith Nephew Plc Adr Stock (SNN) Company Profile
Compare SNN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNN
Smith Nephew Plc Adr
|
37.49 | 15.83B | 5.81B | 412.00M | 0 | 0.94 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Smith Nephew Plc Adr Stock (SNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-25 | Downgrade | HSBC Securities | Buy → Hold |
| Mar-12-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-24 | Downgrade | Berenberg | Buy → Hold |
| Nov-01-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-24 | Initiated | Deutsche Bank | Buy |
| Jun-05-24 | Upgrade | UBS | Neutral → Buy |
| Nov-28-23 | Upgrade | Barclays | Underweight → Equal Weight |
| Nov-03-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-31-23 | Upgrade | HSBC Securities | Hold → Buy |
| Oct-13-23 | Initiated | Stifel | Hold |
| Aug-08-23 | Upgrade | UBS | Sell → Neutral |
| Apr-27-23 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-12-22 | Initiated | Citigroup | Buy |
| Nov-28-22 | Downgrade | UBS | Neutral → Sell |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-28-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-15-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-22 | Upgrade | Redburn | Sell → Neutral |
| Jun-09-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-18-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-01-20 | Initiated | Barclays | Overweight |
| Jul-29-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-21-19 | Initiated | Citigroup | Buy |
| Nov-12-19 | Initiated | Bernstein | Outperform |
| Jul-23-19 | Upgrade | Berenberg | Hold → Buy |
| Feb-08-19 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Jan-02-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-10-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-01-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-25-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-11-17 | Initiated | Canaccord Genuity | Buy |
| Feb-27-17 | Downgrade | Goldman | Buy → Neutral |
| Jan-19-17 | Initiated | HSBC Securities | Hold |
| Dec-08-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-06-16 | Downgrade | Berenberg | Buy → Hold |
| Feb-26-16 | Initiated | Cantor Fitzgerald | Hold |
View All
Smith Nephew Plc Adr Stock (SNN) Latest News
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Smith & Nephew Earnings: The Turnaround Started Three Years Ago and Now Bears Fruit - Morningstar
Smith & Nephew's Turnaround Pushes Profitability Higher - Morningstar
Smith & Nephew plc ADR: Rising 11.43% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
Smith & Nephew SNATS, Inc. (SNN) Stock Forecasts - Yahoo Finance
What Are Expectations For Smith & Nephew plc ADR (NYSE: SNN) In The Short Term? - stocksregister.com
Upwork Inc (NASDAQ: UPWK) Is Down -0.17% – Is It A Buying Opportunity? - stocksregister.com
Advanced Wound Care Market to Hit $19.32 Billion by 2030 – What’s Fueling the Surge? | MarketsandMarkets™. - GlobeNewswire Inc.
Haleon PLC Sponsored ADR (NYSE:HLN) Shares Sold by Bank of New York Mellon Corp - Defense World
Validea's Top Health Care Stocks Based on Martin Zweig - AInvest
SNN’s 2023 Market Dance: Up 12.53% – Time to Invest? - investchronicle.com
Bessemer Group Inc. Purchases 1,701 Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) - Defense World
Smith & Nephew (LON:SN) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World
Smith & Nephew appoints new Non-Executive Director - Investing.com
Smith & Nephew plc: Institutional Strength and Dividend Discipline Fuel Undervalued Gem - AInvest
Study shows patients treated with Smith+Nephew’s CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹ - The Globe and Mail
Shell Plc Declares Q1 2025 Dividend - DirectorsTalk Interviews
Smith & Nephew plc ADR [SNN] Investment Appeal on the Rise - knoxdaily.com
TRI (Thomson-Reuters Corp) may reap gains as insiders became active recently - knoxdaily.com
Glaukos Corporation (GKOS) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Smith+Nephew reports solid Q1 2025 growth - Investing.com
AN Stock Sees Surge of Approximately 3.05% in Last Five Days - knoxdaily.com
Smith+Nephew schedules Q1 2025 trading report release - Investing.com
UBS cuts Smith & Nephew stock rating to Neutral, sets GBP1.25 target - Investing.com
Smith & Nephew releases 2024 annual financial report By Investing.com - Investing.com UK
FTSE 100 up; Smith & Nephew surges; BAE gets UK defence boost - Investing.com UK
Smith+Nephew to announce 2024 full year results February 25 - Investing.com
Smith+Nephew appoints new Non-Executive Director - Investing.com
Rio Tinto Plc 2025 Dividend Schedule And Key Event Dates - DirectorsTalk Interviews
World adrs in Stocks Markets - richtv.io
Smith & Nephew Sees Challenges in China Market - Morningstar
The Best Healthcare Stocks to Buy - Morningstar
Europe First Aid Market Size & Outlook, 2023-2030 - Grand View Research
Healthcare Sector - Morningstar
7 Robotic Surgery Stocks to Buy for the Future of Healthcare - Yahoo Finance
Weekly Upgrades and Downgrades - Yahoo Finance
Validea Detailed Fundamental AnalysisSNN - Nasdaq
Zimmer Biomet Holdings Inc. stock outperforms market on strong trading day - MarketWatch
Zimmer Biomet Holdings Inc. stock falls Thursday, underperforms market - MarketWatch
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Zimmer Biomet Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Zimmer Biomet Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Zimmer Biomet Holdings Inc. stock rises Monday, outperforms market - MarketWatch
Smith Nephew Plc Adr Stock (SNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):